Clinical experience with ramucirumab: outcomes in breast cancer

Bibliography

• AmericanCancerSociety. Breast. cancer facts & figures 2013 – 2014. 2013. Available from: http://www.cancer.org/research/cancerfactsstatistics/breast-cancer-facts-figures [Cited on 22 April 2014]
   Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42
   PubMed Web of Science ®Google Scholar
• Stephenson JA, Goddard JC, Al-Taan O, et al. Tumour angiogenesis: a growth area–from john hunter to judah folkman and beyond. J Cancer Res 2013;2013:6
   Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285(21):1182-6
   PubMed Web of Science ®Google Scholar
• Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 2014;17(3):471-94
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144(5):646-74
   PubMed Web of Science ®Google Scholar
• Miller KD, Dul CL. Breast cancer: the role of angiogenesis and antiangiogenic therapy. Hematol Oncol Clin North Am 2004;18(5):1071-86, ix
   PubMed Web of Science ®Google Scholar
• Ruohola JK, Valve EM, Karkkainen MJ, et al. Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. Mol Cell Endocrinol 1999;149(1-2):29-40
   PubMed Web of Science ®Google Scholar
• Konecny GE, Meng YG, Untch M, et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004;10(5):1706-16
   PubMed Web of Science ®Google Scholar
• Aprile G, Bonotto M, Ongaro E, et al. Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use. Drugs 2013;73(18):2003-15
   PubMed Web of Science ®Google Scholar
• Clarke JM, Hurwitz HI. Targeted inhibition of VEGF receptor 2: an update on ramucirumab. Expert Opin Biol Ther 2013;13(8):1187-96
   PubMed Web of Science ®Google Scholar
• Spratlin JL, Mulder KE, Mackey JR. Ramucirumab (IMC-1121B): a novel attack on angiogenesis. Future Oncol 2010;6(7):1085-94
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383(9911):31-9
   PubMed Web of Science ®Google Scholar
• American Society of Clinical Oncology. FDA Approves Ramucirumab for Gastric or Gastroesophageal Junction Adenocarcinoma. 2014. Available from: http://www.asco.org/fda-approves-ramucirumab-gastric-or-gastroesophageal-junction-adenocarcinoma [Cited on 22] [April 2014]
   Google Scholar
• Tewari KS, Sill MW, Long HJIII, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014;370(8):734-43
   PubMed Web of Science ®Google Scholar
• Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23(4):792-9
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357(26):2666-76
   PubMed Web of Science ®Google Scholar
• Brufsky AM, Hurvitz S, Perez E, et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2011;29(32):4286-93
   PubMed Web of Science ®Google Scholar
• Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28(20):3239-47
   PubMed Web of Science ®Google Scholar
• Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29(10):1252-60
   PubMed Web of Science ®Google Scholar
• FDA. 2011. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm279485.htm
   Google Scholar
• EMEA. 2010. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/12/news_detail_001166.jsp&mid+WCobo1ac058004d5c1
   Google Scholar
• Fojo T, Wilkerson J. Bevacizumab and breast cancer: the E2100 outlier. Lancet Oncol 2010;11(12):1117-19
   PubMed Web of Science ®Google Scholar
• Gianni L, Romieu GH, Lichinitser M, et al. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 2013;31(14):1719-25
   PubMed Web of Science ®Google Scholar
• Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381(9863):303-12
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-90
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24
   PubMed Web of Science ®Google Scholar
• Barrios CH, Liu MC, Lee SC, et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010;121(1):121-31
   PubMed Web of Science ®Google Scholar
• Robert NJ, Saleh MN, Paul D, et al. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. Clin Breast Cancer 2011;11(2):82-92
   PubMed Web of Science ®Google Scholar
• Crown JP, Dieras V, Staroslawska E, et al. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol 2013;31(23):2870-8
   PubMed Web of Science ®Google Scholar
• Baselga J, Segalla JG, Roche H, et al. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol 2012;30(13):1484-91
   PubMed Web of Science ®Google Scholar
• Bergh J, Bondarenko IM, Lichinitser MR, et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol 2012;30(9):921-9
   PubMed Web of Science ®Google Scholar
• Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clini Oncol 2009;27(33):5538-46
   PubMed Web of Science ®Google Scholar
• Schneider BP, Shen F, Miller KD. Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment. Lancet Oncol 2012;13(10):e427-36
   PubMed Web of Science ®Google Scholar
• Schneider BP, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26(28):4672-8
   PubMed Web of Science ®Google Scholar
• Miles DW, de Haas SL, Dirix LY, et al. Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J cancer 2013;108(5):1052-60
   PubMed Web of Science ®Google Scholar
• Wadhwa R, Elimova E, Shiozaki H, et al. Anti-angiogenic agent ramucirumab: meaningful or marginal? Expert Rev Anticancer Ther 2014;14(4):367-79
   PubMed Web of Science ®Google Scholar
• Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010;28(5):780-7
   PubMed Web of Science ®Google Scholar
• Zhu AX, Finn RS, Mulcahy M, et al. A Phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res 2013;19(23):6614-23
   PubMed Web of Science ®Google Scholar
• Vahdat LT, Miller K, JA S. Randomized phase II study of capecitabine with or without ramucirumab (IMC-1121B) or IMC-18F1 in patients with unresectable, locally advanced or metastatic breast cancer (mBC) previously treated with anthracycline and taxane therapy [abstract TPS151]. J Clin Oncol 2011;29(suppl)
   Google Scholar
• ClinicalTrials.gov. A Study of ramucirumab (IMC-1121B) in combination with eribulin versus eribulin alone in patients with breast cancer. 2014. Available from: http://clinicaltrials.gov/ct2/show/NCT01427933?term=ramucirumab&rank=11 [Cited on 22 April 2014]
   Google Scholar
• Mackey J, Gelmon K, Martin M, et al. TRIO-012: a multicenter, multinational, randomized, double-blind phase III study of IMC-1121B plus docetaxel versus placebo plus docetaxel in previously untreated patients with HER2-negative, unresectable, locally recurrent or metastatic breast cancer. Clin Beast Cancer 2009;9(4):258-61
   PubMed Web of Science ®Google Scholar
• TheASCOPost. Addition of novel antiangiogenic agent of no benefit in metastatic breast cancer. 2013. Available from: http://www.ascopost.com/issues/february-15,-2014/addition-of-novel-antiangiogenic-agent-of-no-benefit-in-metastatic-breast-cancer.aspx [Cited on 22 April 2014]
   Google Scholar
• Wilke H, Van Cutsem E, Cheul Oh S, Bodoky G. RAINBOW: a global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE). J Clin Oncol 2014;32
   Web of Science ®Google Scholar
• Garon EB, Cao D, Alexandris E, et al. A randomized, double-blind, phase III study of Docetaxel and Ramucirumab versus Docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale and study design. Clinical lung cancer 2012;13(6):505-9
   PubMed Web of Science ®Google Scholar
• Lilly E. Lilly announces ramucirumab phase III lung cancer trial meets primary endpoint of overall survival. 2014. Available from: https://investor.lilly.com/releasedetail.cfm?ReleaseID=826569 [Cited on 22 April 2014]
   Google Scholar
• Garon EB, Ciuleanu T-E, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. The Lancet 2014. Available from: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960845-X/abstract
   PubMedGoogle Scholar
• Garcia-Carbonero R, Rivera F, Maurel J, et al. An open-label phase ii study evaluating the safety and efficacy of ramucirumab combined with mfolfox-6 as first-line therapy for metastatic colorectal cancer. Oncologist 2014;19(4):350-1
   PubMed Web of Science ®Google Scholar